Objectif Over 45,000 people die each year in Europe – and 255,000 worldwide – from cancers of the brain and central nervous system. Gliomas are the biggest killer, accounting for a third of all diagnoses and 80% of primary malignant brain tumours. Among these glioblastoma is the most common, most aggressive and deadliest. Standard of care treatment offers little hope for patients diagnosed with gliomas: there is no cure, the median survival is 14.6 months and the 2-year survival rate is 13.5%. Conventional therapies can reduce tumour bulk, but they are ineffective at killing the cancer stem cells that drive tumour progression. Curtana may have found the answer. Its novel approach targets a transcription factor, Olig2, which is instrumental in tumorigenesis, tumour expansion and survival. By inhibiting Olig2, Curtana’s small molecule compound, CT-179, kills cancer stem cells. Pre-clinical results show CT-179 to be cytotoxic in selected tumours, a potent radiosensitiser, orally bioavailable and well tolerated; it also crosses the blood-brain barrier and has a high therapeutic index relative to conventional cancer drugs. Most importantly, it increases survival rates (in early studies, median improvement was 68%). Results indicate it may have benefit for other cancers too – any in which Olig2 is highly expressed, including all gliomas and other cancers such as lung, ovarian and endometrial. The Phase 1 project will address the feasibility of carrying out the further pre-clinical and clinical studies required before Curtana can apply for drug marketing approval. This will include identification of clinical partners for multi-centre trials that would be carried out in Europe in Phase 2, as well as potential investors. Champ scientifique natural sciencesbiological sciencesneurobiologymedical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinesurgerymedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicineoncology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur CURTANA PHARMA LTD Contribution nette de l'UE € 50 000,00 Adresse 72 GREAT SUFFOLK STREET SE1 0BL LONDON Royaume-Uni Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région London Inner London — East Lewisham and Southwark Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
